Kiniksa Pharmaceuticals International, plc (KNSA) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 28 days, typically, give or take 13 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Oct 27, 2026before open 27 8-K
Q2 FY2026Tue, Jul 28, 2026before open 28 8-K
Q1 FY2026Tue, Apr 28, 2026before open 28 8-K
Q4 FY2025Tue, Feb 24, 2026before open 55 8-K
Q3 FY2025Tue, Oct 28, 2025before open 28 8-K
Q2 FY2025Tue, Jul 29, 2025before open 29 8-K
Q1 FY2025Tue, Apr 29, 2025before open 29 8-K
Q4 FY2024Tue, Feb 25, 2025before open 56 8-K

What they guided beta

Q3 FY2026 "EX-99.1 2 knsa-ex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – ​ London – October 27, 2026 – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company de" exhibit
Q3 FY2026 "We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million." exhibit
Q3 FY2026 "We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe." exhibit
Q3 FY2026 "Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027." exhibit
Q3 FY2026 "Kiniksa expects to initiate a Phase 1 first-in-human clinical trial of KPL-1161 with a target profile of quarterly subcutaneous (SC) dosing by the end of 2026. ​ Financial Results" exhibit
Q2 FY2026 "EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing" exhibit
Q2 FY2026 "As a result, we have raised our 2026 ARCALYST net sales guidance to between $980 and $995 million,” said Sanj K." exhibit
Q2 FY2026 "We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe." exhibit
Q2 FY2026 "The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026. ​ * Reported as median (95% confidence interval). 1 Treatment Response is defined as Pain Response (NRS score ≤ 2 on the 11-point daily pericarditis pain NRS pain scale) and at least one CRP level ≤ 0.5 mg/dL within 7 days before or after the Pain Response. 2 CRP Normalization is defined as CRP ≤ 0.5 mg/dL. 2 Financial Results" exhibit
Q2 FY2026 "As of June 30, 2026, Kiniksa had $525.9 million of cash, cash equivalents, and short-term investments and no debt. ​ Financial Guidance" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KNSA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KNSA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

KNSA earnings date badge

HTML

<a href="https://veritasdata.dev/company/KNSA/"><img src="https://veritasdata.dev/embed/KNSA.svg" alt="KNSA earnings date" width="240" height="56"></a>

Markdown

[![KNSA earnings date](https://veritasdata.dev/embed/KNSA.svg)](https://veritasdata.dev/company/KNSA/)

Script

<script async src="https://veritasdata.dev/embed/KNSA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KNSA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.